23.4 C
New York
Sunday, July 3, 2022

Aptose Biosciences Inc (APTO) stock plummeted in the after-hours. Here’s the reason

Aptose Biosciences Inc (APTO) stock remained bullish in the regular trading session after gaining 4.07% from the previous day’s session. APTO stock was trading at $1.28 before the closing of the regular session. On the last check, APTO plummeted during the after-hours and lost 14.06% to $1.1 per share. APTO stock continued to move between $1.21 and $1.28 during the recently traded session. Aptose stock plummeted after the company published the fiscal performance for Q4 and FY21. Moreover, the firm also filed form 10-K with the SEC on 22 March 2022.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Aptose Biosciences, Inc. is a preliminary oncology organization, which takes part in the revelation, exploration, and advancement of treatments against cancer. The firm has a market capitalization of $118.05 million. APTO has its headquarters in North York, Ontario, Canada.

APTO Key Financials

Aptose Biosciences Inc reported the financial results for the last quarter and full year for FY2021, which concluded on 31 December 2021. The company reported a total loss of $24.3 million in the last quarter of FY21 versus the total loss of $14.7 million in the year-ago period. This marks an increase of 65.3% in the total loss. Moreover, the company had a total loss of $65.4 million in FY21 compared to $55.2 million during the last year. The total loss in FY21 increased by 18.4%.

APTO reported the loss of $0.73 per stock in FY2021 against the loss of $0.67 per stock in FY2020. This shows an expansion of 8.9%.

CEO Remarks

The CEO of Aptose Bioscience Inc, William G. Rice commented that during the last quarter of the previous year, they announced five complete reductions and one fractional abatement from the 80mg portion extension accomplice of 239. 239 is a Myeloid Kinome Inhibitor (MKI) that objectives all types of FLT3, SYK, types of c-KIT, and JAK kinases. He further added that they are as of now selecting patients for 160 mg portion extension and anticipate giving more subtleties during the Q2 of FY22.

APTO News

Earlier this month, the company declared the participation of its CEO in Oppenheimer’s 32nd health conference. The conference took place on 15 March 2022. The management of APTO also held person-to-person meetings at the conference.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

[class^="wpforms-"]
[class^="wpforms-"]